Center of Excellence CDMO for biopharmaceuticals

Batavia Biosciences is a contract development and manufacturing organization with expertise in viral vaccines, virotherapy, proteins and antibodies. We are not your standard CDMO – our customers regularly refer to us as their product development partner and thought partner.

Viral vectors

Viral vaccines

Proteins & Antibodies

How Batavia helps to reduce human suffering from infectious diseases and cancer

We accelerate the journey to the clinic by improving product yields, reducing process development time and increasing product stability. Our services and technologies have demonstrated to reduce risks, improve timelines and reduce costs in biopharmaceutical development to ensure the product reaches the patient without any unnecessary delays.

Learn more


experts with industry experience


projects successfully completed


successful runs under GMP


returning customers

Latest resources from learning center

Batavia enters the commercial manufacturing business

| Featured, News | No Comments
Leiden, The Netherlands, June 28, 2022 – Today, Batavia Biosciences announces that it will extend its CDMO services portfolio (R&D and clinical manufacturing) to include commercial manufacturing services. The company…

Batavia produces lentivirus for first patient in the Netherlands successfully treated with stem cell gene therapy

| News | No Comments
It is with great enthusiasm and excitement that we would like to congratulate Leiden University Medical Center and the research team on their recent accomplishment using the lentivirus. Researchers have successfully…
Beagle Expansion

Batavia Biosciences increases capacity for viral vectors and vaccine R&D in Netherlands.

| News | No Comments
Leiden, The Netherlands,  June 14, 2022 – Today, Batavia Biosciences announces the expansion of its headquarters and R&D capacities in the Netherlands. The infrastructure increases capacity with another 22,500 sq.…

Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective

| Featured, Scientific publication | No Comments
Adenoviruses are being explored as vectors for cardiovascular gene therapy purposes against many heritable diseases. Gene transfer vectors, based on human adenovirus serotype 5, were some of the first developed…

Talk to our experts

Alfred Luitjens - Bioprocess expert
Alfred Luitjens

Global Technical Sales Director
+31 (0) 88 9950600

Send us a message